AstraZeneca PLC (AZN) vs Novo Nordisk A/S (NVO)
- AstraZeneca PLC AZN 175.62 +0.10%
- Novo Nordisk A/S NVO 38.57 −0.82%
AstraZeneca PLC and Novo Nordisk A/S are both Drug Manufacturers General companies. AstraZeneca PLC is the larger, with a market value of $272.1B against $128.6B — 2.1× the size. Novo Nordisk A/S trades at the lower P/E: 9.8× against 24.6×. Novo Nordisk A/S grew revenue faster over the last twelve months: 11.1% against 7.32%. Novo Nordisk A/S has the higher net margin (34.1% vs 17.7%) and the higher return on invested capital (29.6% vs 12.3%). Both pay a dividend; Novo Nordisk A/S yields more (4.62% vs 1.83%). Across the 23 metrics below, Novo Nordisk A/S leads on 18 and AstraZeneca PLC on 5.
Valuation
Profitability
| Metric | AZN | NVO | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 81.94% | 80.89% | 73.01% |
| Operating margin | 23.68% | 42.66% | 18.34% |
| Net margin | 17.68% | 34.09% | 7.31% |
| Free cash flow margin | 10.15% | 13.25% | 18.56% |
| Return on equity | 22.56% | 58.84% | 20.02% |
| Return on assets | 9.41% | 20.52% | 2.28% |
| Return on invested capital | 12.31% | 29.63% | 6.26% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack